Research programme: erythropoietin oral - HanAll Biopharma

Drug Profile

Research programme: erythropoietin oral - HanAll Biopharma

Alternative Names: EPO agent - HanAll Biopharma; HL033

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nautilus Biotech
  • Developer HanAll Biopharma
  • Class Erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Anaemia; Renal failure

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anaemia in South Korea (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Renal-failure in South Korea (PO)
  • 21 Sep 2010 Research programme: erythropoietin oral - HanAll Pharmaceutical is available for licensing www.hanallbiopharma.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top